TCG Lifesciences Limited (TCGLS) has announced that it has entered into a strategic agreement with JSW Lifesciences (JSW), a full services EU based CRO, to strengthen its R&D offerings in the area of Central Nervous System (CNS). This agreement will enable TCGLS and JSW to offer specialized preclinical and early clinical development services in the neuroscience domain to their combined customer base.
Mr. Swapan Bhattacharya, Managing Director, TCGLS said about the deal, “TCGLS is pleased to partner with JSW to advance its expertise in the area of CNS and deliver innovative preclinical and early clinical development R&D solutions. This collaboration will add a new dimension to TCGLSs’ present offerings in the integrated drug discovery domain.”
Dr. Manfred Windisch, CEO, JSW Lifesciences, said, “Partnering with TCGLS gives us the opportunity to take advantage of ‘India benefit’ and work closely for mutual growth. Most important for us is the outstanding quality and the expertise of our partner. We are confident that this strategic tie-up will be highly beneficial to both. “
Contact TCG Lifesciences:
Corporate Affairs Department
TCG Lifesciences Limited
Mobile: +91 9810730653, email: [email protected]
Contact JSW Lifesciences:
Corporate Affairs Department
JSW-Lifesciences GmbH
Tel: +43-316-258111-110, email: [email protected]
About JSW Lifesciences
JSW Lifesciences is a full service contract research organization. The company performs preclinical as well as clinical research. JSW Lifesciences has profound expertise in neuroscience and more than a decade of experience in contract research resulting in a sustainable advantage for the customers. JSW is a world leading specialist for transgenic disease model in the field of neurological indications. Learn more at www.jswresearch.com
About TCG Lifesciences Limited
TCG Lifesciences Limited is a leading Contract Research Services, clinical research, and laboratory informatics company with operations in India, Europe, Japan, and the United States. It is part of The Chatterjee Group, a global investment conglomerate headquartered in New York. TCGLS collaborates to service the multi-disciplinary research efforts of global pharmaceutical and biotechnology companies through its three units: Chembiotek (Discovery Research), Clininvent (Clinical Research Solutions), and LabVantage (Enterprise Informatics). It has trust based relationships with a majority of the global pharmaceutical companies. The relationships span from specific solutions and sourcing services to integrated projects across multiple domains to complete translational research programs in the drug discovery and development space. Learn more at www.tcgls.com